BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12187328)

  • 1. Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial.
    Neri B; Doni L; Fulignati C; Perfetto F; Turrini M; Andreoli F; Pantalone D; Pernice LM; Taruffi F; Martini V; Poma A; Valeri A; Bacci G; Sancez L; Moretti R
    Anticancer Drugs; 2002 Aug; 13(7):719-24. PubMed ID: 12187328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial.
    Scheithauer W; Kornek GV; Ulrich-Pur H; Penz M; Raderer M; Salek T; Haider K; Kwasny W; Depisch D
    Cancer; 2001 Apr; 91(7):1264-71. PubMed ID: 11283925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).
    Cascinu S; Graziano F; Ferraù F; Catalano V; Massacesi C; Santini D; Silva RR; Barni S; Zaniboni A; Battelli N; Siena S; Giordani P; Mari D; Baldelli AM; Antognoli S; Maisano R; Priolo D; Pessi MA; Tonini G; Rota S; Labianca R
    Ann Oncol; 2002 May; 13(5):716-20. PubMed ID: 12075739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study.
    Khouri C; Guiu B; Cercueil JP; Chauffert B; Ladoire S; Ghiringhelli F
    Anticancer Drugs; 2010 Jul; 21(6):656-61. PubMed ID: 20216061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study.
    Santini D; Massacesi C; D'Angelillo RM; Marcucci F; Campisi C; Vincenzi B; Pilone A; Bianco V; Bonsignori M; Tonini G
    Med Oncol; 2004; 21(1):59-66. PubMed ID: 15034215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Raltitrexed and oxaliplatin in colorectal cancer: in vitro and in vivo study of a synergistic cytostatic combination].
    Schüll B; Scheithauer W
    Acta Med Austriaca; 2002; 29(4):124-31. PubMed ID: 12424937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.
    Schüll B; Kornek GV; Schmid K; Raderer M; Ulrich-Pur H; Fiebiger W; Schneeweiss B; Lenauer A; Depisch D; Scheithauer W
    Onkologie; 2002 Aug; 25(4):358-62. PubMed ID: 12232488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.
    Rosati G; Rossi A; Germano D; Reggiardo G; Manzione L
    Anticancer Res; 2003; 23(3C):2981-5. PubMed ID: 12926149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Gedlicka C; Schüll B; Brugger S; Schneeweiss B; Lang F; Lenauer A; Depisch D
    J Clin Oncol; 2002 Jan; 20(1):165-72. PubMed ID: 11773166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event.
    Wenzel C; Urbauer E; Schwarz C; Funk G; Oehler L; Kornek GV; Scheithauer W
    Anticancer Drugs; 2006 Aug; 17(7):865-8. PubMed ID: 16926637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
    Sato A; Kurihara M; Horikoshi N; Aiba K; Kikkawa N; Shirouzu K; Mitachi Y; Sakata Y; Wakui A
    Anticancer Drugs; 1999 Sep; 10(8):741-8. PubMed ID: 10573207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
    Carnaghi C; Zucali P; Garassino I
    Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.
    Fizazi K; Ducreux M; Ruffié P; Bonnay M; Daniel C; Soria JC; Hill C; Fandi A; Poterre M; Smith M; Armand JP
    J Clin Oncol; 2000 Jun; 18(11):2293-300. PubMed ID: 10829050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
    Lloyd Jones M; Hummel S; Bansback N; Orr B; Seymour M
    Health Technol Assess; 2001; 5(25):1-128. PubMed ID: 11990245
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
    Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.
    Seitz JF; Bennouna J; Paillot B; Gamelin E; François E; Conroy T; Raoul JL; Becouarn Y; Bertheault-Cvitkovic F; Ychou M; Nasca S; Fandi A; Barthelemy P; Douillard JY
    Ann Oncol; 2002 Jul; 13(7):1072-9. PubMed ID: 12176786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer.
    Cortinovis D; Bajetta E; Di Bartolomeo M; Dognini G; Beretta E; Ferrario E; Ricotta R; Buzzoni R
    Tumori; 2004; 90(2):186-91. PubMed ID: 15237580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma.
    Laudani A; Gebbia V; Leonardi V; Savio G; Borsellino N; Cusimano MP; Calabria C; Stefano R; Agostara B
    Anticancer Res; 2004; 24(2C):1139-42. PubMed ID: 15154638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltitrexed-based chemotherapy for advanced colorectal cancer.
    Liu Y; Wu W; Hong W; Sun X; Wu J; Huang Q
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):219-25. PubMed ID: 24388340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.